ArticlePloS one2015
Individualizing risk of multidrug-resistant pathogens in community-onset pneumonia.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Burden of pneumococcal disease among adults in Southern Europe (Spain, Portugal, Italy, and Greece): a systematic review and meta-analysis.Human vaccines & immunotherapeutics · 2021Pooled it
- Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America.American journal of respiratory and critical care medicine · 2019Guideline
- The global epidemiology of MRSA.JAC-antimicrobial resistance · 2026Review
- The appropriateness of initial intravenous empirical antibiotic consumption guided by digital antimicrobial stewardship tool: a correlation with the usage of antibiotics from the access and watch groups in ten Indonesian hospitals.Frontiers in digital health · 2026Article
- Bloodstream infections due to multi-drug resistant bacteria in the emergency department: prevalence, risk factors and outcomes-a retrospective observational study.Internal and emergency medicine · 2025Observational
- Aerobic bacteria study, clinical spectrum, and outcome of patients with community-acquired multidrug-resistant pathogens.Journal of family medicine and primary care · 2024Article
- Considerations about antibiotic management for community-acquired pneumonia: unmet needs and future perspectives.Internal and emergency medicine · 2024Article
- A score to predict Pseudomonas aeruginosa infection in older patients with community-acquired pneumonia.BMC infectious diseases · 2023Article
- Efficacy of cefiderocol- vs colistin-containing regimen for treatment of bacteraemic ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii in patients with COVID-19.International journal of antimicrobial agents · 2023Observational
- Identify Drug-Resistant Pathogens in Patients with Community-Acquired Pneumonia.Advances in respiratory medicine · 2023Review
- How and when to manage respiratory infections out of hospital.European respiratory review : an official journal of the European Respiratory Society · 2022Review
- In-hospital mortality associated with community-acquired pneumonia due to methicillin-resistant Staphylococcus aureus: a matched-pair cohort study.BMC pulmonary medicine · 2021Article
- Early antibiotic treatment in emergency department: the critical balance.Internal and emergency medicine · 2021Article
- Too Much or Too Little Empiric Treatment forAnnals of the American Thoracic Society · 2021Article
- Efficacy of a Fosfomycin-Containing Regimen for Treatment of Severe Pneumonia Caused by Multidrug-Resistant Acinetobacter baumannii: A Prospective, Observational Study.Infectious diseases and therapy · 2021Article
- Community-acquired Pneumonia Owing to Multidrug-Resistant Pathogens: A Step toward an Early Identification.Annals of the American Thoracic Society · 2021Article
- Incidence of Antibiotic Treatment Failure in Patients with Nursing Home-Acquired Pneumonia and Community Acquired Pneumonia.Infectious disease reports · 2021Article
- Healthcare-associated pneumonia: a prospective study in Spain.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2020Observational
- Distribution and drug resistance of pathogenic bacteria in emergency patients.World journal of clinical cases · 2019Article
- Clinical Prediction Score for Community-Onset Bloodstream Infections Caused by Extended-Spectrum Beta-Lactamase-ProducingJournal of Korean medical science · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe diffusion of multidrug-resistant (MDR) bacteria has created the need to identify risk factors for acquiring resistant pathogens in patients living in the community.
objectiveTo analyze clinical features of patients with community-onset pneumonia due to MDR pathogens, to evaluate performance of existing scoring tools and to develop a bedside risk score for an early identification of these patients in the Emergency Department. PATIENTS AND
methodsThis was an open, observational, prospective study of consecutive patients with pneumonia, coming from the community, from January 2011 to January 2013. The new score was validated on an external cohort of 929 patients with pneumonia admitted in internal medicine departments participating at a multicenter prospective study in Spain.
resultsA total of 900 patients were included in the study. The final logistic regression model consisted of four variables: 1) one risk factor for HCAP, 2) bilateral pulmonary infiltration, 3) the presence of pleural effusion, and 4) the severity of respiratory impairment calculated by use of PaO2/FiO2 ratio. A new risk score, the ARUC score, was developed; compared to Aliberti, Shorr, and Shindo scores, this point score system has a good discrimination performance (AUC 0.76, 95% CI 0.71-0.82) and calibration (Hosmer-Lemeshow, χ2 = 7.64; p = 0.469). The new score outperformed HCAP definition in predicting etiology due to MDR organism. The performance of this bedside score was confirmed in the validation cohort (AUC 0.68, 95% CI 0.60-0.77).
conclusionPhysicians working in ED should adopt simple risk scores, like ARUC score, to select the most appropriate antibiotic regimens. This individualized approach may help clinicians to identify those patients who need an empirical broad-spectrum antibiotic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.